Hung Do Sells 25,000 Shares of Amicus Therapeutics Inc. (FOLD) Stock
Amicus Therapeutics Inc. (NASDAQ:FOLD) insider Hung Do sold 25,000 shares of Amicus Therapeutics stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $7.25, for a total value of $181,250.00. Following the completion of the sale, the insider now owns 558,453 shares in the company, valued at approximately $4,048,784.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Hung Do also recently made the following trade(s):
- On Tuesday, September 6th, Hung Do sold 25,000 shares of Amicus Therapeutics stock. The shares were sold at an average price of $7.00, for a total value of $175,000.00.
Shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) opened at 7.51 on Friday. Amicus Therapeutics Inc. has a one year low of $4.98 and a one year high of $11.78. The firm’s 50-day moving average price is $7.21 and its 200 day moving average price is $6.95. The stock’s market cap is $1.07 billion.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.07. Equities research analysts expect that Amicus Therapeutics Inc. will post ($1.35) EPS for the current fiscal year.
Large investors have recently bought and sold shares of the company. FMR LLC boosted its stake in Amicus Therapeutics by 1.6% in the second quarter. FMR LLC now owns 19,023,053 shares of the biopharmaceutical company’s stock valued at $103,865,000 after buying an additional 299,950 shares during the period. Redmile Group LLC boosted its stake in Amicus Therapeutics by 3.6% in the second quarter. Redmile Group LLC now owns 11,106,446 shares of the biopharmaceutical company’s stock valued at $60,641,000 after buying an additional 388,026 shares during the period. Vanguard Group Inc. boosted its stake in Amicus Therapeutics by 8.1% in the second quarter. Vanguard Group Inc. now owns 7,033,500 shares of the biopharmaceutical company’s stock valued at $38,404,000 after buying an additional 524,050 shares during the period. BlackRock Fund Advisors boosted its stake in Amicus Therapeutics by 6.3% in the second quarter. BlackRock Fund Advisors now owns 5,785,314 shares of the biopharmaceutical company’s stock valued at $31,588,000 after buying an additional 340,915 shares during the period. Finally, Pictet Asset Management Ltd. boosted its stake in Amicus Therapeutics by 674.9% in the second quarter. Pictet Asset Management Ltd. now owns 4,707,381 shares of the biopharmaceutical company’s stock valued at $33,328,000 after buying an additional 4,099,881 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.
FOLD has been the topic of a number of research analyst reports. Leerink Swann restated an “outperform” rating and issued a $19.00 target price (up previously from $17.00) on shares of Amicus Therapeutics in a research report on Tuesday, June 14th. Zacks Investment Research upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price objective on the stock in a report on Monday, July 25th. Finally, Chardan Capital set a $15.00 price objective on Amicus Therapeutics and gave the company a “buy” rating in a report on Thursday, August 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $12.19.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.